LENSAR (LNSR) Stock Price, News & Analysis

Company Overview

LENSAR, Inc., a commercial-stage medical device company, focuses on designing, developing, and marketing a femtosecond laser system for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism. It offers LENSAR Laser System that incorporates a range of proprietary technologies designed to assist the surgeon in obtaining visual outcomes, efficiency, and reproducibility by providing imaging, procedure planning, design, and precision. The company also offers ALLY Adaptive Cataract Treatment System, a platform design to femtosecond laser technology features that enhanced laser capabilities into a single small unit that allows surgeons to perform a femtosecond laser assisted cataract procedure in a single operating room. LENSAR, Inc. was incorporated in 2004 and is headquartered in Orlando, Florida.

Key Stats

• Today's Range: $7.53 to $7.95
• 50-Day Range: $4.83 to $7.89
• 52-Week Range: $2.33 to $8.17
• Volume: 15,955 shs
• Average Volume: 34,585 shs
• Market Capitalization: $87.93 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $8.00
• Consensus Rating: Buy

LENSAR Stock Analysis - MarketRank™

LENSAR scored higher than 15% of companies evaluated by MarketBeat, and ranked 889th out of 950 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.5 / 5
• Analyst Rating: Buy

Consensus Rating

LENSAR has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

LENSAR has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of LENSAR is -5.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of LENSAR is -5.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

LENSAR has a P/B Ratio of 2.55. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.64% of the float of LENSAR has been sold short.

Short Interest Ratio / Days to Cover

LENSAR has a short interest ratio ("days to cover") of 1.5, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in LENSAR has recently increased by 33.64%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

LENSAR does not currently pay a dividend.

Dividend Growth

LENSAR does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.64% of the float of LENSAR has been sold short.

Short Interest Ratio / Days to Cover

LENSAR has a short interest ratio ("days to cover") of 1.5, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in LENSAR has recently increased by 33.64%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 1.4 / 5
• News Sentiment: N/A

News Sentiment

LENSAR has a news sentiment score of -0.50. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.54 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 1 news article for LENSAR this week, compared to 1 article on an average week.

Search Interest

2 people have searched for LNSR on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, LENSAR insiders have not sold or bought any company stock.

Percentage Held by Insiders

66.00% of the stock of LENSAR is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

40.15% of the stock of LENSAR is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

LNSR Stock Analysis - Frequently Asked Questions

How have LNSR shares performed this year?

LENSAR's stock was trading at $3.51 on January 1st, 2024. Since then, LNSR stock has increased by 115.7% and is now trading at $7.57.
View the best growth stocks for 2024 here.

How were LENSAR's earnings last quarter?

LENSAR, Inc. (NASDAQ:LNSR) announced its earnings results on Thursday, May, 9th. The company reported ($0.19) earnings per share (EPS) for the quarter. The company earned $10.59 million during the quarter. LENSAR had a negative trailing twelve-month return on equity of 49.02% and a negative net margin of 34.03%.

Who are LENSAR's major shareholders?

Top institutional investors of LENSAR include Geode Capital Management LLC (0.86%) and Sanctuary Advisors LLC (0.17%). Insiders that own company stock include Thomas R Staab II and Gary M Winer.
View institutional ownership trends.

How do I buy shares of LENSAR?

Shares of LNSR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of LENSAR own?

Based on aggregate information from My MarketBeat watchlists, some other companies that LENSAR investors own include Arch Capital Group (ACGL), Aprea Therapeutics (APRE), Artelo Biosciences (ARTL), AstraZeneca (AZN), Baidu (BIDU), Cidara Therapeutics (CDTX) and The Carlyle Group (CG).

Company Calendar

• Last Earnings: 5/09/2024
• Today: 12/18/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Surgical & medical instruments
• Sub-Industry: Medical Equipment
• Current Symbol: NASDAQ:LNSR
• CUSIP: N/A
• CIK: 1320350
• Web: www.lensar.com
• Phone: 888-536-7271
• Fax: N/A
• Employees: 110
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $8.00
• High Stock Price Target: $8.00
• Low Stock Price Target: $8.00
• Potential Upside/Downside: +3.2%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($1.46)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-14,380,000.00
• Net Margins: -34.03%
• Pretax Margin: -34.03%
• Return on Equity: -49.02%
• Return on Assets: -21.12%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 3.37
• Quick Ratio: 2.10

Sales & Book Value

• Annual Sales: $48.87 million
• Price / Sales: 1.84
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.97 per share
• Price / Book: 2.61

Miscellaneous

• Outstanding Shares: 11,615,000
• Free Float: 7,141,000
• Market Cap: $90.02 million
• Optionable: Optionable
• Beta: 0.70